patent.fyi
Applications  /  US 2026/0355197
United States Patent Application Publication

US 2026/0355197 A1

Published
Nov 12, 2026
Filed
Jun 10, 2026
Earliest date on the face
Dec 15, 2023
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Parameter or scale variation

Two daily oral dosing windows

A dispensing package holds two oral units of the selected compound for each 24-hour period. The two compartments carry administration times 12 hours apart, such as 08:00 and 20:00. Each unit contains half of the prescribed daily amount, and the subject swallows one unit at each scheduled time.

Combination with existing systems

Oral dosing with pharmacy barcode verification

A pharmacy dispensing workstation connects a barcode scanner to an electronic prescription system. Each package barcode identifies the selected compound, unit strength, and lot. The workstation compares the scanned identity and strength with the prescription, flags mismatches, and records the lot of each package released for oral administration.

Automated or data-driven variant

Sensor logging of dose access

A blister card holds oral units of the selected compound over individually monitored conductive traces. Removing a unit breaks its trace, and a battery-powered recorder stores the cavity identifier and event time. Software compares each opening time with its scheduled dosing window and displays the opening record alongside the subject’s separate intake confirmation.

Symptom tracking alongside oral dosing

An electronic diary collects a daily itch rating on a 0 to 10 scale and records the time of each reported oral dose. Software groups the entries into seven-day intervals and plots the mean itch rating alongside the number of reported doses. The display shows the number of diary entries behind each weekly mean and leaves intervals with zero entries blank.

Specific version of a part

Oral calcineurin inhibition

An oral capsule contains a calcineurin inhibitor that binds an intracellular immunophilin. The resulting complex inhibits calcineurin and reduces transcription of cytokines involved in T-cell activation.

Single daily oral dose

A single oral dose contains 100 mg of one selected compound from A, B, or C. The subject takes the dose once daily.

Two divided oral doses

Two oral doses each contain 50 mg of the same selected compound from A, B, or C. The subject takes one dose in the morning and one in the evening for a total of 100 mg per day.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2022/0016088 A1
Published
Jan 20, 2022
Filed
Jul 14, 2021
Class
A61K 31/426
Document BUS 2022/0016087 A1
Published
Jan 20, 2022
Filed
Jul 14, 2021
Class
A61K 31/426
Claim 1
Document A
Document B
1.1the step of orally administering to a subject in need thereof Compound A, B, or C
Described herein are unit oral dose compositions that reduce the severity of heartburn or the risk of the occurrence of heartburn in a human in need of taking ibuprofen for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen at a dosage from about 50 mg to about 400 mg per unit oral
A · US 2022/0016088 A1 · ¶ 3
Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking naproxen sodium for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) naproxen sodium at a dosage from about 100 mg to about 440
B · US 2022/0016087 A1 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
While generally regarded as safe, effective treatments for acute pain and fever, the use of non-prescription-strength, or over-the-counter (OTC), non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen can be associated with stomach problems such as heartburn.
A · US 2022/0016088 A1 · ¶ 2
Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific compounds, synthetic methods, or uses as such may, of course, vary.
A · US 2022/0016088 A1 · ¶ 5
While generally regarded as safe, effective treatments for acute pain and fever, the use of non-prescription-strength, or over-the-counter (OTC), non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen sodium can be associated with stomach problems such as heartburn.
B · US 2022/0016087 A1 · ¶ 2
Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific compounds, synthetic methods, or uses as such may, of course, vary.
B · US 2022/0016087 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355197 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355197/, SHA-256 c6381c2d1ae31840108986ad1f41646f07ad4d4b20eda5198db0bca50d5fbcc3
First published
Permanent addresshttps://patent.fyi/US20260355197/
Content fingerprint (SHA-256)c6381c2d1ae31840108986ad1f41646f07ad4d4b20eda5198db0bca50d5fbcc3
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi